- Home
- SBLK vs MIRM Comparison
SBLK vs MIRM Comparison
Compare SBLK & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- MIRM
- Stock Information
- Founded
- SBLK 2006
- MIRM 2018
- Country
- SBLK Greece
- MIRM United States
- Employees
- SBLK N/A
- MIRM N/A
- Industry
- SBLK Marine Transportation
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- SBLK Consumer Discretionary
- MIRM Health Care
- Exchange
- SBLK Nasdaq
- MIRM Nasdaq
- Market Cap
- SBLK 1.8B
- MIRM 1.9B
- IPO Year
- SBLK N/A
- MIRM 2019
- Fundamental
- Price
- SBLK $14.97
- MIRM $41.51
- Analyst Decision
- SBLK Strong Buy
- MIRM Strong Buy
- Analyst Count
- SBLK 3
- MIRM 12
- Target Price
- SBLK $25.00
- MIRM $57.58
- AVG Volume (30 Days)
- SBLK 2.5M
- MIRM 418.0K
- Earning Date
- SBLK 02-10-2025
- MIRM 11-12-2024
- Dividend Yield
- SBLK 16.22%
- MIRM N/A
- EPS Growth
- SBLK 10.39
- MIRM N/A
- EPS
- SBLK 2.98
- MIRM N/A
- Revenue
- SBLK $1,220,003,000.00
- MIRM $307,028,000.00
- Revenue This Year
- SBLK $17.35
- MIRM $82.14
- Revenue Next Year
- SBLK $7.09
- MIRM $26.18
- P/E Ratio
- SBLK $4.96
- MIRM N/A
- Revenue Growth
- SBLK 24.41
- MIRM 112.14
- 52 Week Low
- SBLK $14.59
- MIRM $23.14
- 52 Week High
- SBLK $27.47
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- SBLK 20.41
- MIRM 43.16
- Support Level
- SBLK $14.59
- MIRM $40.03
- Resistance Level
- SBLK $15.36
- MIRM $43.37
- Average True Range (ATR)
- SBLK 0.44
- MIRM 1.82
- MACD
- SBLK -0.06
- MIRM -0.51
- Stochastic Oscillator
- SBLK 8.90
- MIRM 22.01
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.